ERBB2 and CDH1-related diffuse gastric and lobular breast cancer syndrome: Resistance to endocrine therapy has also been associated with co-mutations in NF1 and HER2, particularly in relapsed LBC, suggesting that HER2-targeted therapies such as neratinib may be effective in select cases [7].